Literature DB >> 14557240

C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?

Gavin J Blake1, Paul M Ridker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14557240     DOI： 10.1152/ajpregu.00227.2003

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN： 0363-6119            Impact factor:   3.619


× No keyword cloud information.
  9 in total

Review 1.  Inflammation in atherosclerosis and diabetes mellitus.

Authors:  Jorge Plutzky
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 2.  Periodontal disease and risk of atherosclerotic coronary heart disease.

Authors:  Takako Nakajima; Kazuhisa Yamazaki
Journal:  Odontology       Date:  2009-07-29       Impact factor: 2.634

3.  Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease.

Authors:  John H Peters; Tammy Greasby; Nancy Lane; Anthony Woolf
Journal:  Biomarkers       Date:  2009-06       Impact factor: 2.658

4.  C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.

Authors:  D E Laaksonen; L Niskanen; K Nyyssönen; K Punnonen; T-P Tuomainen; V-P Valkonen; R Salonen; J T Salonen
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

5.  The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-a levels.

Authors:  Levent Kebapcilar; Oktay Bilgir; Elif Cetinkaya; Murat Akyol; Ferda Bilgir; Giray Bozkaya
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

6.  Periodontal, metabolic, and cardiovascular disease: Exploring the role of inflammation and mental health.

Authors:  Mark A Reynolds; Anwar T Merchant; Teodor T Postolache; Hina Makkar; Abhishek Wadhawan; Aline Dagdag
Journal:  Pteridines       Date:  2018-11-13       Impact factor: 0.581

7.  Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).

Authors:  Anna Sicuranza; Ilaria Ferrigno; Elisabetta Abruzzese; Alessandra Iurlo; Sara Galimberti; Antonella Gozzini; Luigiana Luciano; Fabio Stagno; Antonella Russo Rossi; Nicola Sgherza; Daniele Cattaneo; Corrado Zuanelli Brambilla; Cristina Marzano; Carmen Fava; Olga Mulas; Emanuele Cencini; Adele Santoni; Vincenzo Sammartano; Alessandro Gozzetti; Luca Puccetti; Monica Bocchia
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

8.  C-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression.

Authors:  Marta M Turu; Mark Slevin; Sabine Matou; David West; Cristina Rodríguez; Ana Luque; Marta Grau-Olivares; Lina Badimon; Jose Martinez-Gonzalez; Jerzy Krupinski
Journal:  BMC Cell Biol       Date:  2008-09-02       Impact factor: 4.241

9.  Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Authors:  Monica Bocchia; Sara Galimberti; Lara Aprile; Anna Sicuranza; Antonella Gozzini; Francesca Santilli; Elisabetta Abruzzese; Claudia Baratè; Barbara Scappini; Giulia Fontanelli; Monika Malgorzata Trawinska; Marzia Defina; Alessandro Gozzetti; Alberto Bosi; Mario Petrini; Luca Puccetti
Journal:  Oncotarget       Date:  2016-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.